Status:
COMPLETED
A Study of Disease Progression and Anti-HIV Treatments
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/9...
Eligibility Criteria
Inclusion Criteria
Patients must have:
- Prior participation on protocol ACTG 175.
PER AMENDMENT 8/27/96:
- Patients must be on study/on treatment at the time the protocol study treatment is extended.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
October 1 1998
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT00001068
End Date
October 1 1998
Last Update
November 4 2021
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Therapeutics CRS
Birmingham, Alabama, United States, 35294
2
USC CRS
Los Angeles, California, United States, 90033
3
UCLA CARE Center CRS
Los Angeles, California, United States, 90095
4
Stanford CRS
Palo Alto, California, United States, 94115